参附注射液治疗心力衰竭的系统评价

目的系统评价西药常规加参附注射液与单纯西药常规比较治疗心力衰竭的临床疗效及安全性。方法计算机检索CNKI(1979.01～2009.12)、VIP(1989.01～2009.12)、CBM(1978～2009)、PubMed(1978～2009.12)和Cochrane图书馆(2009年第4期),并手工检索相关杂志,搜集西药常规加参附注射液与单纯西药常规比较治疗心力衰竭的临床随机对照试验,按照Cochrane协作网等推荐的方法评价纳入研究的方法学质量和提取有效数据后,采用RevMan5.0.2软件进行Meta分析。结果共纳入16个研究,合计1?117例患者,其研究质量均为C级。Meta分析结果显示,西药常规加参附注射液与单纯西药常规治疗比较:能显著改善心衰患者症状,提高临床综合疗效RR=3.30,95%CI(2.22,4.92),P<0.000 01];显著改善心衰患者中医证候,提高生活质量RR=6.85,95%CI(2.90,16.17),P<0.000 01];增加左室射血分数WMD=3.54,95%CI(2.78,4.30),P<0.000 01];对左室舒张末内径的减小有较为明显的正性作用WMD=2.43,95%CI(1.04,3.82),P=0.000 6]。此外同时,还分别有1项研究显示参附注射液可能有增加6分钟步行距离,降低IL-6及TNF-α水平,减少Lee氏心衰积分和LVD-36问卷积分的作用。结论西药常规加参附注射液较单纯西药常规治疗心力衰竭可进一步提高临床疗效。

Shenfu Injection for Patients with Heart Failure: A Systematic Review

Objective To evaluate the clinical therapeutic effect and safety of western medicine plus Shenfu Injection versus simple western medicine in heart failure(HF) patients.Methods Such databases as CNKI(January 1979 to 2009),VIP(January 1989 to December 2009),CBM(1978 to 2009),PubMed(1978 to December 2009),The Cochrane Library(Issue 4,2009) and relevant journals were searched,and the literature of randomized controlled trials comparing the combination of western medicine and Shenfu Injection with simple western...